RT Journal Article
SR Electronic
T1 IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.01.20048561
DO 10.1101/2020.04.01.20048561
A1 Gritti, Giuseppe
A1 Raimondi, Federico
A1 Ripamonti, Diego
A1 Riva, Ivano
A1 Landi, Francesco
A1 Alborghetti, Leonardo
A1 Frigeni, Marco
A1 Damiani, Marianna
A1 Micò, Caterina
A1 Fagiuoli, Stefano
A1 Cosentini, Roberto
A1 Lorini, Ferdinando Luca
A1 Gandini, Lucia
A1 Novelli, Luca
A1 Morgan, Jonathan P
A1 Owens, Benjamin M J
A1 Kanhai, Karan J K
A1 Reljanovic, Gordana Tonkovic
A1 Rizzi, Marco
A1 Di Marco, Fabiano
A1 Rambaldi, Alessandro
YR 2020
UL http://medrxiv.org/content/early/2020/06/20/2020.04.01.20048561.abstract
AB Background Severe COVID-19 is characterised by interstitial pneumonia and hyperinflammation, with elevated levels of pro-inflammatory cytokines, such as IL-6. Effective treatments are urgently needed, and IL-6 is a rational target to reduce hyperinflammation.Methods An observational, control cohort, single-centre study initiated at the Papa Giovanni XXIII Hospital in Bergamo, Italy included patients with COVID-19 confirmed by a nasopharyngeal swab positive for severe acute respiratory syndrome coronavirus 2 RNA and interstitial pneumonia requiring ventilatory support. Patients were treated with either best supportive care and siltuximab or best supportive care alone. Propensity score matching was applied to minimise differences in baseline covariates between patient cohorts. The main outcome was mortality in siltuximab-treated patients compared with patients in the matched-control cohort. This study (Siltuximab in Severe COVID-19, SISCO) is registered with ClinicalTrials.gov, identifier NCT04322188.Findings Thirty patients received siltuximab, while 188 control patients received only best supportive care. Siltuximab-treated patients were matched to 30 control patients using the propensity score analysis of baseline covariates. The 30-day mortality rate was significantly lower in the siltuximab-treated than the matched-control cohort patients (HR 0·462, 95% CI 0·221– 0·965); p=0·0399). The mean follow-up was 33·3 days (range 7–58 days) for the siltuximab-treated patients and 22·8 days (range 2–45 days) for the control cohort. Sixteen siltuximab-treated patients were discharged from hospital, four remained on mechanical ventilation, and 10 patients died.Interpretation Patients with rapidly progressing COVID-19 respiratory failure requiring ventilatory support may benefit from treatment with siltuximab to reduce mortality and cytokine-driven hyperinflammation associated with severe disease. These findings require validation in a randomised controlled clinical trial.Funding Papa Giovanni XXIII Hospital and the Italian Association for Cancer Research funded the study. EUSA Pharma supplied siltuximab, and provided funding for data collection, analysis, and development of the publication.Competing Interest StatementDeclaration of interests Jonathan P Morgan, Benjamin MJ Owens and Karan JK Kanhai are employees of EUSA Pharma. Alessandro Rambaldi reports consultancy fees from Amgen, Novartis, Pfizer, Celgene, Italfarmaco, Gilead, Roche and Omeros, travel support from Amgen, Novartis, Celgene, Italfarmaco, Gilead and Roche, and research grants from Amgen, Italfarmaco and Roche, outside the submitted work. Caterina Mico reports travel support from Medac, outside the submitted work. Diego Ripamonti reports personal fees from Gilead, Janssen and ViiV, outside the submitted work. Fabiano Di Marco reports grants from Boehringer Ingelheim, GSK, Novartis and AZ, and personal fees from Boehringer Ingelheim, GSK, Chiesi, Zambon, Novartis, Guidotti/Malesci, AZ, Menarini, Mundipharma, TEVA and Almiral, outside the submitted work. Guiseppe Gritti reports non-financial support from Gilead Kite, Roche, Takeda and Janssen, and personal fees from Gilead Kite, Autolus, Roche, IQvia, Takeda, Amgen and Italfarmaco, outside the submitted work. Ivano Riva reports travel support from Aferetica outside the submitted work. Stefano Fagiuoli reports grants from Gilead and Novartis and personal fees from Gilead, Abbvie, MSD, Novartis, Bayer, Astellas, Kedrion, and Intercept, outside the submitted work. All other authors declare no competing interests. Clinical TrialNCT04322188Funding StatementPapa Giovanni XXIII Hospital and the Italian Association for Cancer Research funded the study. EUSA Pharma supplied siltuximab, and provided funding for data collection, analysis, and development of the publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available upon reasonable requests submitted to the authors.